About
GenSight Biologics develops gene therapies targeting inherited retinal neurodegenerative diseases to restore vision, currently advancing treatments such as lenadogene nolparvovec (GS010) and GS030 in clinical trials.
Explore GenSight Biologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.